Net profit of Caplin Point Laboratories rose 13.87% to Rs 130.80 crore in the quarter ended September 2024 as against Rs 114.87 crore during the previous quarter ended September 2023. Sales rose 17.81% to Rs 483.10 crore in the quarter ended September 2024 as against Rs 410.06 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales483.10410.06 18 OPM %34.0833.51 - PBDT185.22157.76 17 PBT168.46146.00 15 NP130.80114.87 14 Powered by Capital Market - Live

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2024Powered by Capital Market - Live

Hindustan Zinc Ltd, Godfrey Phillips India Ltd, Angel One Ltd, Triveni Engineering and Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 19 August 2024.Caplin Point Laboratories Ltd registered volume of 42.47 lakh shares by 14:14 IST on NSE, a 22.69 fold spurt over two-week average daily volume of 1.87 lakh shares. The stock rose 12.37% to Rs.1,781.60. Volumes stood at 70156 shares in the last session.Hindustan Zinc Ltd witnessed volume of 206.02 lakh shares by 14:14 IST on NSE, a 8.34 times surge over two-week average daily volume of 24.70 lakh shares. The stock dropped 4.49% to Rs.496.55. Volumes stood at 113.19 lakh shares in the last session.Godfrey Phillips India Ltd clocked volume of 8.7 lakh shares by 14:14 IST on NSE, a 6.44 times surge over two-week average daily volume of 1.35 lakh shares. The stock gained 11.08% to Rs.5,038.10. Volumes stood at 2.37 lakh shares in the last session.Angel One Ltd saw volume of 34.87 lakh shares by 14:14 IST on NSE, a 6.44 fold spurt over two-week average daily volume of 5.42 lakh shares. The stock increased 8.76% to Rs.2,349.45. Volumes stood at 3.85 lakh shares in the last session.Triveni Engineering and Industries Ltd notched up volume of 60.1 lakh shares by 14:14 IST on NSE, a 6.13 fold spurt over two-week average daily volume of 9.81 lakh shares. The stock rose 9.09% to Rs.453.00. Volumes stood at 5.41 lakh shares in the last session.Powered by Capital Market - Live

The domestic equity benchmarks traded with decent gains in morning trade. The Nifty traded above the 24,550 mark. Media shares advanced for the second consecutive trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex, rose 20.55 points or 0.03% to 80,460.37. The Nifty 50 index added 18 points or 0.07% to 24,559.15. The broader market outperformed the frontline indices, the S&P BSE Mid-Cap index added 0.52% and the S&P BSE Small-Cap index gained 1.19%. The market breadth was strong. On the BSE, 2,643 shares rose and 1,031 shares fell. A total of 160 shares were unchanged. Economy: India's forex reserves declined $4.8 billion to $670.119 billion for the week ended August 9, according to the latest RBI data. In the previous reporting week, the country's foreign exchange reserves had increased $7.533 billion to an all-time high of $674.919 billion. For the week ended August 9, foreign currency assets, a major component of the reserves, decreased by $4.079 billion to $587.96 billion. Gold reserves declined by $860 million to $59.239 billion during the week. The special drawing rights (SDRs) were up by $121 million to $18.282 billion. India's reserve position with the IMF increased by $18 million to $4.638 billion in the reporting week, the central bank data showed. Buzzing Index: The Nifty Media index added 2.17% to 2,104.35. The index advanced 4.31% in the two trading sessions. V18 Broadcast (up 4.21%), Network 18 Media & Investments (up 3.05%), Saregama India (up 2.64%), PVR Inox (up 2.6%), Hathway Cable & Datacom (up 1.78%), Tips Industries (up 1.75%), Dish TV India (up 1.24%), Zee Entertainment Enterprises (up 1.15%), Nazara Technologies (up 0.55%) and Sun TV Network (up 0.21%) edged higher. Stocks in Spotlight: Caplin Point Laboratories soared 8.40% after the Brazilian Health Regulatory Agency (ANVISA) conducted inspection at its Chennai facility between 12 and 16 August 2024 and concluded with zero observations. Techno Electric & Engineering Company (Techno Electric) hits upper circuit of 5% after the company partnered with IndiGrid to develop two IndiGrid's Greenfield interstate transmission Systems (ISTS) projects. Glenmark Pharmaceuticals added 2.89% after the company's subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution. Powered by Capital Market - Live

ANVISA conducted an inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi between 12 and 16 August 2024 and concluded with zero observations. Chairman, C.C.Paarthipan said, 'It is indeed gratifying to have two back to back audits with zero observations. We remain steadfast in our commitment to maintaining the highest levels of quality compliance at all our sites. Brazil is an important part of our expansion plans in Latin America and this clearance opens the door to the largest market in that geography.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms. The company's consolidated net profit jumped 19.8% to Rs 124.92 crore on 16.1% increase in revenue from operations to Rs 458.96 crore in Q1 FY25 over Q1 FY24. The scrip hit all time high of Rs 1,732.80 in today's intraday session. Powered by Capital Market - Live

Caplin Point Laboratories informed that ANVISA conducted an inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi, in Chennai in Tamil Nadu. Chairman Mr.C.C.Paarthipan added 'It is indeed gratifying to have two back to back audits with Zero observations. We remain steadfast in our commitment to maintaining the highest levels of quality compliance at all our sites. Brazil is an important part of our expansion plans in Latin America and this clearance opens the door to the largest market in that geography.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms. The company's consolidated net profit jumped 19.8% to Rs 124.92 crore on 16.1% increase in revenue from operations to Rs 458.96 crore in Q1 FY25 over Q1 FY24. Shares of Caplin Point Laboratories added 1.68% to end at Rs 1,585.75 on Friday, 16 August 2024. Powered by Capital Market - Live

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 125%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Caplin Point Laboratories announced that the 33th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

Net profit of Caplin Point Laboratories rose 19.86% to Rs 123.97 crore in the quarter ended June 2024 as against Rs 103.43 crore during the previous quarter ended June 2023. Sales rose 16.10% to Rs 458.96 crore in the quarter ended June 2024 as against Rs 395.32 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales458.96395.32 16 OPM %33.0832.01 - PBDT170.34138.37 23 PBT154.38126.99 22 NP123.97103.43 20 Powered by Capital Market - Live

Profit before tax (PBT) increased 21.6% YoY to Rs 154.38 crore in Q1 FY25. EBITDA jumped to Rs 170.37 crore in Q1 FY25, registering the growth of 23% YoY, aided by new products launches. EBITDA margin stood at 35.7% in Q1 FY25 as against 34% in Q1 FY24. The company's LatAM business shows strong revenue and bottom-line growth with robust cashflows. Branded generic segment drives growth in profitability with specialty products including Softgels and Pre-Filled Syringes. The generics segment contributes 70% of the company's revenue while branded generics segment contributes 30%. Caplin One Labs Oncology site commences exports to LatAm, Company targets breakeven revenue within next 12 months. Product registration work ongoing in 7 countries in LatAm including Mexico. In US & regulated markets, Caplin Steriles records impressive revenue growth through enhanced automation and improved productivity. Caplin Steriles USA Inc. will launch first products by October 2024 and plans to launch 35 products in 12 months. The company said that it has allocated an overall Capex budget of approximately Rs 600-650 crore for the investment projects, most of which are nearing completion. The intended Capex aims to enhance existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process. C.C. Paarthipan, Chairman said, 'Our company continues to be an outlier, whether its taking the road less travelled in Latin America, or focusing on our Cashflow and Bottom line rather than unsustainable or inconsistent top line growth. We're pleased to report yet another strong set of numbers for this quarter. LatAm is a key driver of growth but we're now also supported by strong performance from the US. As we embark on launching our own frontend in the US, we remain confident that our pattern of success through taking the road less travelled would repeat itself in the biggest markets in the world as well.' Caplin Point Laboratories is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company has manufacturing facilities that cater to a complete range of finished dosage forms.Powered by Capital Market - Live